Moderna Stock Pops as FDA Application Moves Forward

Pharma giant Moderna Inc (NASDAQ:MRNA) is enjoying a boost today, after the U.S. Food & Drug Administration (FDA) accepted the company's flu vaccine application for review. The company made modifications to the application after it was rejected last week. MRNA was last seen up 5.7% to trade at $46.45, heading for a third-straight gain as it moves back toward its Jan. 22 more than one-year high of $55.20. Since the start of the year, the equity is already up 55.4%. A bout of short covering could help push Mo ...